Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DIANEAL PD 2 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-2 with Dextrose 3.5% is a peritoneal dialysis solution. Dextrose provides an osmotic gradient that facilitates the removal of uremic toxins and excess fluid from the blood across the peritoneal membrane into the dialysate. The solution also contains electrolytes to correct imbalances.
Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.
2 to 3 liters intraperitoneally, 4 exchanges daily, with dwell times of 4-6 hours for CAPD; or 2 to 2.5 liters intraperitoneally, cycler-assisted, 3-5 cycles nightly for APD. Dextrose 3.5% solution used based on ultrafiltration needs.
Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.
None Documented
None Documented
The elimination half-life of dextrose from the systemic circulation is approximately 3.5-4.5 hours after intraperitoneal administration. Clinically, this reflects the rate of glucose absorption and metabolism, which can be altered in patients with impaired glucose tolerance or diabetes.
Not applicable via systemic absorption; glucose absorbed from dialysate exhibits a terminal half-life of 1.5–2 hours in plasma, reflecting rapid cellular uptake and metabolism.
Peritoneal dialysis (PD) with 3.5% dextrose solution results in elimination of excess fluid and solutes via the peritoneal membrane. Dextrose is absorbed systemically and metabolized. The primary route of elimination of dialytic waste products (e.g., urea, creatinine) is via the peritoneal fluid itself, which is drained. Less than 1% of dextrose is excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal: negligible; primarily eliminated via peritoneal dialysis (dialysate outflow). Biliary/fecal: <1%.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution